English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, July 26, 2022
Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
Tuesday, June 21, 2022
Sirnaomics于第四届RNA疗法:从概念到临床专题讨论会上汇报其专有的GalAhead™双靶点RNAi疗法的最新进展
Sirnaomics於第四屆RNA療法:從概念到臨床專題討論會上匯報其專有的GalAhead™雙靶點RNAi療法的最新進展
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead(TM) Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
Thursday, June 16, 2022
Sirnaomics于同行评审刊物《皮肤病药物杂志》发表公司核心产品 STP705治疗成人原位鳞状细胞皮肤癌临床研究结果
Sirnaomics於同行評審刊物《皮膚病藥物雜誌》發表公司核心產品 STP705治療成人原位鱗狀細胞皮膚癌臨床研究結果
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
Monday, May 30, 2022
Sirnaomics启动RNAi治疗药物STP705进行用于医学美容治疗的成人腹部减脂整形I期临床研究
Sirnaomics啟動RNAi治療藥物STP705進行用於醫學美容治療的成人腹部減脂整形I期臨床研究
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575